CuraGenesis

CuraGenesis is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies. Founded by Dr. Xiaohu (Frank) Fan, the former co-founder and CSO of Legend Biotech, the company leverages its proprietary platforms to create highly efficient CAR-T therapies. Their core technologies include Cura-InVivo for in vivo cell programming and Cura-Fast for rapid ex vivo manufacturing, aiming to reduce costs and improve patient access. The company's lead programs target hematological malignancies such as multiple myeloma and B-cell lymphomas. CuraGenesis is headquartered in Suzhou, China, with additional research facilities in Shanghai. By integrating advanced synthetic biology with clinical expertise, the company seeks to transform the landscape of curative medicine for cancer patients worldwide.